Intellectual Property: Patent Law
O’Melveny thwarts attacks against our clients that threaten industry-leading technology, critical product lines, and blockbuster therapeutics.
O’Melveny thwarts attacks against our clients that threaten industry-leading technology, critical product lines, and blockbuster therapeutics.
O'Melveny is a trusted partner to some of the world’s top technology companies when it comes to high-stakes patent litigation. We know just how much time, effort, and creativity it takes to bring new products, pharmaceuticals, and services to market, and we work side by side with our clients to help protect the full value of those investments. Whether we’re enforcing intellectual property rights or defending against baseless claims, our focus is always on safeguarding the technologies that make our clients stand out.
Our patent litigation team brings together deep technical know-how and smart legal strategy. The team includes electrical and microchip engineers, computer scientists, software developers, physicists, chemists, biologists, and mathematicians, many with advanced degrees and real-world industry experience. Among us is even a NASA Exceptional Achievement Medal recipient who helped design the deep-space communication systems used to reach Mars rovers. We understand that the language of the courtroom isn’t the same as the language of the lab, and we’re skilled at breaking down complex concepts for judges and juries in ways that lead to great results for our clients.
We put these skills to work wherever our clients need us. We have extensive experience before the US International Trade Commission, the US Patent and Trademark Office, and federal courts across the country, particularly in districts known for patent litigation. Our attorneys have successfully protected key intellectual property across a wide range of industries, from consumer electronics and semiconductors to pharmaceuticals, biotechnology, medical devices, media, and telecommunications.
Prevailed at trial and secured a US$39 million jury verdict enforcing a patent covering the eyelash growth drug, Latisse®.
Successfully defended AMD in multiple matters involving semiconductor technology.
Brought four waves of Hatch-Waxman litigation involving AstraZeneca’s breast cancer treatment Faslodex®. Several matters resolved just prior to or during trial. We also defeated seven IPRs, and managed the company’s worldwide patent litigation on the product.
Stepping in just before trial, won a jury verdict for the tech giant in West Texas, defeating patent infringement claims against Google’s popular smart-home Nest Hub devices.
Secured multiple victories protecting Hulu’s core technology for on-demand live streaming.
Scored an important appellate victory for Hyundai Motor America in the Federal Circuit holding that automobile dealers are not agents of their distributors—a decision that will impact plaintiffs seeking to establish venue based on an agency relationship.
Won at trial in Hatch-Waxman patent infringement litigation involving Onyx’s multiple myeloma cancer drug Kyprolis® - all Onyx patent claims found valid and infringed; affirmed on appeal.
Protected Samsung’s best-selling products in a host of patent cases in the ITC, US District Courts across the country, the USPTO, and on appeal.
Secured precedent-setting victories on motions to transfer patent cases out of the Western District of Texas, weakening patent plaintiffs’ ability to handpick their venues and cementing our reputation as a leading force in the area.
“The O’Melveny team has great knowledge of the subject matter. They are very experienced, efficient and impressive.”
—Chambers (2024)
O’Melveny “is of world-class quality. It is a top firm for difficult patent litigation and is particularly strong on the defence side, but this experience also makes it powerful when acting for plaintiffs, too.”
—IAM Patent 1000 (2023)
“O’Melveny & Myers LLP’s practice maintains a strong foothold in the main US patent litigation venues, with a focus on hardware to software, augmented reality to streaming video, e-commerce and digital technology to pharmaceuticals, acting on the defense and offense side alike. The group also handles an active Hatch-Waxman and BPCIA caseload.”
—The Legal 500 US (2022)
“Firm of the Year,” Patent Contentious (West)
—Managing IP (2022)
O’Melveny’s “deep bench of patent litigators know exactly when to push and when to give in order to keep costs reasonable. Its practitioners are dedicated to producing high-quality work product in order to achieve the best possible result for clients. The team’s breadth of scientific and legal experience is incredibly impressive.”
—IAM Patent 1000 (2023)